Riley
Senior Member
- Messages
- 178
Video of mitochondria panel is up on OMF Facebook page. Drs. Klimas, Davis, Shungu, and one other guy.
I would like to ask of a link, source, for that... as @greeneagledown did.fourth, a German group didn't find improvement at all (N=10) etc...
I would like to ask of a link, source, for that... as @greeneagledown did.
You are talking of the Charite in Berlin? Just very curious.
http://forums.phoenixrising.me/inde...ss-treating-me-patients-with-rituximab.35955/
That information comes from the linked video (which, as discussed in that thread, contains mostly gibberish).
@Gijs is Dutch, he's born pessimistic.But 2/3 have got significant improvement. How can you not be optimistic about that?
Ron is blowing my mind.
@Gijs is Dutch, he's born pessimistic.J/k.
I would assume the autoimmune subgroup or those w/autoimmune diseases similar to ME/CFS would be most likely to benefit from RTX. Did they say anything about this? I am thinking those with autoimmune POTS antibodies from the Charite or Cell Trend tests would be in the responder group?
Yes, exciting. potential assay in the works, needs to be verified although he does point out that hopefully there will be easier ways in future.Great videostream.
Technology that Dr Davis was talking about is mindblowing.
B
I would like to ask of a link, source, for that... as @greeneagledown did.
You are talking of the Charite in Berlin? Just very curious.
The information comes from Dr Carmen Scheibenbogen in Berlin. It has nothing to do with the Beiger interview although it may have been mentioned there. I am fairly sure there is no publication but the information has been shared with the research community. I agree that we do not know much about inclusion criteria but I doubt these are a major issue. Some cases were very unwell even if not strictly in the severe category (which did not give good responses in Norway).
Although I very much hope the phase III rituximab study is positive I think we should still be cautious.
Yes, exciting. potential assay in the works, needs to be verified although he does point out that hopefully there will be easier ways in future.
Heard him say at one point in response to a question, he didn't want to talk about something because it was too early, did anyone get that bit ?
Apart from the guy who kept interrupting the was a great talk.
It's only through talks like this will we know what's going on because Davis is so far ahead of everyone else when it comes to technology. It's good he lives in Silicon Valley!
wow I thought his " blood microchip " thing would be way more complicated to understand than that,
pretty sure anyone could understand how it works if they have a basic understanding of science.
The information comes from Dr Carmen Scheibenbogen in Berlin. It has nothing to do with the Beiger interview although it may have been mentioned there. I am fairly sure there is no publication but the information has been shared with the research community. I agree that we do not know much about inclusion criteria but I doubt these are a major issue. Some cases were very unwell even if not strictly in the severe category (which did not give good responses in Norway).
Although I very much hope the phase III rituximab study is positive I think we should still be cautious.